Drugs / Bivalent Subtype C gp120
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03284710 Comparator | Jun 2017 → Dec 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent Subtype C gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03284710 ↗ |
| Modality | Vaccine | “a bivalent gp120 protein vaccine boost” PMID 38502656 ↗ Mar 2024 |